485 related articles for article (PubMed ID: 34026868)
1. Metabolism and Chronic Inflammation: The Links Between Chronic Heart Failure and Comorbidities.
Li Z; Zhao H; Wang J
Front Cardiovasc Med; 2021; 8():650278. PubMed ID: 34026868
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial biogenesis: pharmacological approaches.
Valero T
Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
[TBL] [Abstract][Full Text] [Related]
3. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
4. Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts.
Birkenfeld AL; Jordan J; Dworak M; Merkel T; Burnstock G
Pharmacol Ther; 2019 Feb; 194():132-144. PubMed ID: 30149104
[TBL] [Abstract][Full Text] [Related]
5. Reappraising the role of chronic inflammatory burden in heart failure.
Lin X; Song W; Zhang C; Zhou M; Li J
J Gene Med; 2023 Aug; 25(8):e3519. PubMed ID: 37211702
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.
Zeng Q; Zhou Q; Liu W; Wang Y; Xu X; Xu D
Front Cardiovasc Med; 2021; 8():636152. PubMed ID: 33644138
[TBL] [Abstract][Full Text] [Related]
7. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
8. A network pharmacology approach to discover action mechanisms of Yangxinshi Tablet for improving energy metabolism in chronic ischemic heart failure.
Wu RM; Jiang B; Li H; Dang WZ; Bao WL; Li HD; Ye G; Shen X
J Ethnopharmacol; 2020 Jan; 246():112227. PubMed ID: 31509780
[TBL] [Abstract][Full Text] [Related]
9. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease.
Onishi K
J Cardiol; 2017 Aug; 70(2):128-134. PubMed ID: 28325523
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia.
van der Wal HH; Grote Beverborg N; van Veldhuisen DJ; Voors AA; van der Meer P
Expert Opin Pharmacother; 2016 Aug; 17(11):1527-38. PubMed ID: 27254409
[TBL] [Abstract][Full Text] [Related]
11. Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure.
Sharma A; Ezekowitz JA
Can J Diabetes; 2020 Feb; 44(1):103-110. PubMed ID: 31630988
[TBL] [Abstract][Full Text] [Related]
12. Non-cardiovascular comorbidities in heart failure patients and their impact on prognosis.
Correale M; Paolillo S; Mercurio V; Ruocco G; Tocchetti CG; Palazzuoli A
Kardiol Pol; 2021; 79(5):493-502. PubMed ID: 34125921
[TBL] [Abstract][Full Text] [Related]
13. Comorbidities in Heart Failure.
van der Wal HH; van Deursen VM; van der Meer P; Voors AA
Handb Exp Pharmacol; 2017; 243():35-66. PubMed ID: 28382470
[TBL] [Abstract][Full Text] [Related]
14. Emerging Role of Adipocyte Dysfunction in Inducing Heart Failure Among Obese Patients With Prediabetes and Known Diabetes Mellitus.
Berezin AE; Berezin AA; Lichtenauer M
Front Cardiovasc Med; 2020; 7():583175. PubMed ID: 33240938
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory Biomarkers and Therapeutic Targets in Heart Failure.
Papadimitriou L; Kalogeropoulos AP
Curr Med Chem; 2015; 22(23):2716-26. PubMed ID: 25876745
[TBL] [Abstract][Full Text] [Related]
16. Frequent non-cardiac comorbidities in patients with chronic heart failure.
Dahlström U
Eur J Heart Fail; 2005 Mar; 7(3):309-16. PubMed ID: 15718170
[TBL] [Abstract][Full Text] [Related]
17. Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologist's Perspective: Lessons Learned from Cardiovascular Outcome Trials.
Koliaki C; Katsilambros N
Int J Environ Res Public Health; 2019 Dec; 17(1):. PubMed ID: 31878281
[TBL] [Abstract][Full Text] [Related]
18. Possibility of a New Therapeutic Strategy for Left Ventricular Dysfunction in Type 2 Diabetes.
Sakamoto M; Matsutani D; Kayama Y
J Clin Med Res; 2018 Nov; 10(11):799-805. PubMed ID: 30344814
[TBL] [Abstract][Full Text] [Related]
19. Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets.
Ayoub KF; Pothineni NVK; Rutland J; Ding Z; Mehta JL
Cardiovasc Drugs Ther; 2017 Dec; 31(5-6):593-608. PubMed ID: 28956198
[TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanism of the Association Between Atrial Fibrillation and Heart Failure Includes Energy Metabolic Dysregulation Due to Mitochondrial Dysfunction.
Ozcan C; Li Z; Kim G; Jeevanandam V; Uriel N
J Card Fail; 2019 Nov; 25(11):911-920. PubMed ID: 31415862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
